More than one year after the last dose of obinutuzumab/bendamustine, our patient had persistent and pronounced lymphopenia, hypogammaglobulinemia (IgG~200 mg/dL), and no CD20/low CD4 T-cells in peripheral blood by flow cytometry. Here, CD4 is linked to lymphopenia.